This paper describes a likelihood based fine scale association mapping method for estimating the position of a disease causing gene relative to a battery of typed marker loci. The method uses multilocus allele frequency data from a sample of unrelated diseased individuals and from a sample of unrelated control individuals, that is, a case and control type design. This type of data could be obtained by typing DNA pools, which is a less expensive procedure than typing individuals separately. The method described here is robust because it is uses a nonparametric model that makes relatively few assumptions. It can be implemented efficiently, making a multipoint analysis of a data set of a hundred markers feasible.
Introduction
Susceptibility to disease often has a heritable component (McKusick 1998) , implying the existence of one or more disease loci segregating for alleles that influence susceptibility to the disease. It is of natural interest to map these disease loci, which can be achieved by looking for association between disease phenotype and genotype at a battery of marker loci. The many available methods for mapping disease loci can be categorised according to whether they use information from multiple marker loci individually (single point methods) or simultaneously (multipoint methods), and whether the typed individuals are of known relationship (a pedigree study) or are assumed to be unrelated (a case and control study). In addition, methods can be classified by the type of estimation statement they make about the position of the disease locus, which could be a set of p-values, a point estimate, a confidence interval, a likelihood function or a posterior probability distribution.
In this paper I consider only the simplest type of case and control design study, where the disease phenotype is classified simply as affected (or case, referred to here as diseased) or unaffected (referred to here as control). In case and control design studies, if a disease allele is of recent origin and is therefore in strong linkage disequilibrium (LD) with nearby polymorphic markers, and if there is a strong association between the presence of the single disease allele and the disease phenotype (such as a recessive fully penetrant disease allele and no phenocopies) then relatively small sample sizes on the order of a hundred cases and a hundred controls may be adequate for estimating the position of the disease allele (e.g. the study of cystic fibrosis by Kerem et al. 1989 ; see Morris et al. 2002 for a comprehensive review of subsequent analyses of that data). However, for disease alleles that arose a long time in the past so that LD is weak, or when the disease phenotype is weakly correlated with allelic state at the disease locus, larger sample sizes are needed to obtain sufficient information or power Risch 1999, Longmate 2001) . Typing many markers in many individuals is labour intensive, and therefore there is considerable interest in more efficient typing methods. One possible approach is to make use of DNA pools (Arnheim et al. 1985 , Barcellos et al. 1997 , Risch and Teng 1998 , Germer et al. 2000 , Hoogendoorn et al. 2000 , Le Hellard et al. 2002 . Once the pools have been constructed, many individuals can be typed simultaneously, and the laboratory effort thus saved could instead be used to develop and type a greater number of markers. However, three trade-offs have been identified. Firstly, information about allele frequencies obtained from DNA pools is less precise than that obtained by typing individuals because allele frequencies are inferred from peak heights rather than by counting the outcomes of individual typing experiments (Le Hellard et al. 2002) . Secondly, proportions of heterozygous individuals in each pool cannot be estimated (Risch and Teng 1998) . Thirdly, and perhaps most importantly, no useable linkage or phase information is obtained from DNA pools. For example, a pool containing equal numbers of the two haplotypes A 1 B 1 and A 2 B 2 (where A and B are two marker loci and subscripts denote alleles) is indistinguishable from a pool containing equal numbers of all four possible haplotypes. It therefore seems worthwhile to ask under what circumstances more information about the position of a disease allele would be obtained by using DNA pools and typing more markers than by typing individuals at fewer loci. In other words, which is the best strategy? It is immediately clear that this is only an issue if laboratory effort for developing markers and typing is the limiting resource, rather than (say) the number of diseased individuals available for study.
If only single point mapping methods are to be used then phase information is not used in the analysis and therefore nothing would be lost by not obtaining it. DNA pools are therefore expected to be a good strategy compared to individual haplotyping (Risch and Teng 1998) since the loss of precision of allele frequency estimates should be small (see e.g. Barcellos et al. 1997 figure 1 ) and human populations are usually close to Hardy-Weinberg proportions. However, this question is harder to answer if a multipoint mapping method is to be used. The chief obstacle to answering this question has been that, until now, no multipoint method was available for analysing multilocus allele frequency data. Multipoint methods had been developed to analyse haplotype data (Terwilliger 1995 , Xiong and Guo 1997 , Collins and Morton 1998 , McPeek and Strahs 1999 , Morris et al. 2000 , Liu et al. 2001 , Rannala and Reeve 2001 or unresolved diploid genotypes (Liu et al. 2001, Reeve and Rannala 2002) . It is hard to make any meaningful comparison between the likelihood or posterior probability distribution obtained from any of these recent likelihood based multipoint methods and the set of p-values (or likelihood ratios, or LOD (log 10 of the odds) scores) that would be obtained if single point methods were applied to the corresponding allele frequency data one locus at a time.
In this paper I describe a novel likelihood based method for multipoint mapping using multilocus allele frequency data, which is implemented in a computer program poolmap. The inferences made using this method can be compared to those obtained via multipoint analysis of fully resolved haplotypes in a meaningful way. The method developed has two additional interesting features, which may commend its use even if haplotype or diploid genotype are available. The first is that it is computationally rapid, and therefore large data sets can be analysed. The second is that it is robust and conservative. It is robust because the model used is general and assumes little, and it is conservative because the inference is made via a profile likelihood that (unlike the marginal of Bayesian posterior probability distribution) assumes nothing about the values of nuisance parameters that inevitably appear in the model.
Although it will always be less informative than a multipoint analysis of fully resolved haplotypes, the present method complements existing methods. It can be used for preliminary analyses to narrow down region in which full haplotyping should be done, it may be a better method to use than single point methods when markers spanning whole chromosomes have been typed, and it may be a useful check if there is a high level of model uncertainty.
Methods

Assumptions
In this section I state the assumptions of the model in non-mathematical language, before developing a more formal description of the model and inference procedure in section 2.2.
I consider a case and control design study in which samples of unrelated diseased and control individuals have been typed at a battery of marker loci. The data used are the counts of each allele, at each locus and for each group. I assume for simplicity that these counts are known without error. (In reality, if DNA pools had been typed instead of individuals then each count would be the product of an estimated allele frequency and pool size, and there would be some associated uncertainty.) I assume that an equal number of diseased individuals have been typed at each locus. The data required here can clearly be calculated from diploid or haploid genotype data when there are no missing data.
Beyond knowing the order they occur on the chromosome, I make no assumption about the map positions of the marker loci, or about the relationship between physical and map distances.
I assume that the probability of having the disease phenotype is increased by the presence of a disease allele that arose via a unique mutational event at some unknown time in the past. The penetrance and dominance of the effect of this disease allele is Figure 1 : Regardless of the shape of the genealogy at the disease locus, if the disease allele has always been rare (and there have been no two point crossovers) then the amount of haplotype sharing, or number of alleles descended from the ancestral chromosome, in the sample of diseased chromosomes is a monotonic descreasing function of the distance between the disease locus (star) and any marker (black triangle).
arbitrary, and further I allow there to be any number of unrelated phenocopy individuals in the sample of diseased individuals. I assume only that some copies of the disease allele are present in the diseased sample. The history of this sample is best understood in terms of coalescent theory (Kingman 1982 , Hudson 1983 , Nordborg 2001 ) and junction theory (Fisher 1953 , Hudson 1983 , Baird 1995 , as illustrated in figure 1 . First consider the genealogy at the locus where the disease allele segregates. I make absolutely no assumption about the shape of this genealogy. Going back in time all the lineages carrying the disease allele coalesce before reaching a single lineage in which the disease allele arose. In this most recent common ancestor (MRCA) the disease allele was present on a specific chromosome. The genotype of this MRCA is treated as missing data in the model. All the chromosomal material on this MRCA chromosome, and all material descended from it, is labelled ancestral chromosome. All other chromosomal material is labelled non-ancestral chromosome. "Junctions" between "blocks" of different chromosomal material are generated by recombination events. Only junctions between ancestral and non-ancestral blocks are of interest here. The first crucial assumption that I make is that the disease allele is rare at the time of sampling, and has always been rare. This assumption means that all recombination events on the genealogy of disease chromosomes occured with an entirely non-ancestral chromosome. Assuming also that there were no two point crossovers means that all chromosomes in diseased individuals contain at most one ancestral block, within which the disease locus is situated. This implies that the amount of haplotype sharing, or number of alleles descended from the ancestral chromosome, in the sample of diseased chromosomes is a monotonic descreasing function of the distance between the disease locus and any marker locus. The assumption that the disease allele is rare means that I can neglect the possibility of any copies of the disease allele or ancestral blocks of being present in control chromosomes. The second crucial assumption I make is that, for each locus sited in a non-ancestral block, the allele present is assumed to be drawn from some (unknown) distribution for that locus, regardless of whether the chromosome is in the diseased or the control pool. Although mutation is not explicitly modelled, the assumption here is that the unknown distributions represent the balance between mutation and drift at each locus. In other words I assume Hardy-Weinberg proportions and linkage equilibrium for non-ancestral blocks.
The Statistical Model
Let n be the number of marker loci, and let m i be the map position of the i-th marker, with the loci numbered i = 1, 2, . . . , n − 1, n in the order that they occur on the chromosome. If the map positions are unknown then the method works without modification by setting m i = i. The alleles at locus i are represented by a set of integers, e.g. S i = {0, 1, 2, . . .}. Let the count at locus i of allele j in the diseased pool be D ij . The total number of haplotypes in the diseased pool is therefore j∈S i D ij , which is constant for all i by assumption. Likewise C ij is the count at locus i of allele j in the control pool and j∈S i C ij is the total number of haplotypes in the control pool counted at locus i, which need not be constant for all i.
The parameter of principal interest is the position of the disease gene, z ∈ {m i : i = 1, . . . , n}. Obviously m i < z < m i+1 indicates that the disease gene lies between marker loci i and i + 1, and the values z < m 1 and z > m n indicate that the disease gene lies outside the interval spanned by the markers. Let z = max {i : m i < z} denote the index of the nearest marker to the left of the disease allele, and similarly let z = min {i : m i > z} denote the index of the nearest marker to the right of the disease allele.
The other variables we need to formulate the model are two vectors, a and x, and a matrix P. The element a i ∈ S i gives the allele present at locus i on the ancestral chromosome. The element x i gives the number of chromosomes in the diseased sample that have ancestral chromosome at locus i. Under the model assumptions x 1 ≤ x 2 ≤ . . . ≤ x z (the sequence (x 1 , . . . , x z ) is weakly isotonic or order preserving), and x z ≥ x z +1 ≥ . . . ≥ x n (the sequence (x z , . . . , x n ) is weakly antitonic or order reversing). Also, x i ≤ D ia i is required for all i. Finally, the element p ij gives the probability of sampling allele j at locus i in a non-ancestral block, with j∈S i p ij = 1 for all i. The unknowns x and P are parameters that have to be estimated along with z. I treat a as missing data, and assume that it is a random haplotype sampled from a population at linkage equilibrium with allele frequencies given by P.
The unknown a and x in some way "explain" some of the diseased allele counts, because there is probability one of observing at least x i copies of allele a i at locus i. Writing the likelihood function is made easier by subtracting these from the data, writing
for the "unexplained" diseased allele counts, where δ a i j is Kronecker's delta function
(Remember that D * ij is a function of a i and x i even though the notation does not make this explicit.) Fixing values of parameters and the missing data a, the probability of observing the "unexplained" counts at the i-th locus is given by the product of multinomial probabilities
where (e.g.) D i is the i-th row of D, and
is an indicator function that indicates whether a particular (x i , a i ) pair are consistent with the data (and for which a better notation would be good). Equation (3) takes this simple form because of my assumption that allelic state in non-ancestral blocks is independent across individuals. Summing over a is straightforward because the a i are independent, so Pr (a i ;
and so
Finally, because of my assumption that allelic state in non-ancestral blocks is independent across loci, the likelihood function is the product over all loci
All non-independence between loci is modelled by the monotonicity patterns allowed for x. A term depending only on C (which is constant in likelihood based inference) has been absorded into the constant of proportionality in (8).
Note that the position of the disease locus z does not enter directly into the likelihood function, but only enters indirectly via the monotonicity patterns allowed for x, which are dictated by z and z . Thus the likelihood is constant for all m i < z < m i+1 . In other words, the model does not allow estimation of the exact position of the disease locus but only estimation of the intermarker interval that it lies in. This is why the method works in an identical fashion whether the m i are known or are unknown and set to m i = i.
In order to obtain a concise inference about z the nuisance parameters in the model must be eliminated. This can be done by calculating the profile or maximised likelihood (see e.g. Murphy and Van Der Vaart 2000, Sprott 2000 pp.66-72) for the single scalar parameter of interest z, which is defined as
Profile likelihoods are a useful general tool for summarizing multidimensional likelihood surfaces, but see Ghosh (1988 pp.57-59) for a critical view of their routine use. The maximum of the profile likelihood occurs at the same value of z ( z, the MLE or Maximum Likelihood Evaluate) as the maximum of the full likelihood surface, that is
For points away from the maximum the profile likelihood has the simple interpretation of being the maximum likelihood that can be attained for a given value of z when the all the other parameters are unknown and are allowed to vary arbitrarily (Sprott 2000 p.66) . A profile likelihood is therefore a conservative representation of uncertainty. By analogy with ordinary support regions (Edwards 1992 pp.71-72, Sprott 2000 pp.14-15), a c-unit profile support region Z(c) contains the values of z that have profile log likelihood at most c less than the maximum log likelihood,
There is a simple (but to my knowledge hitherto unremarked) equivalence between support intervals and profile support intervals:
Lemma 1. For any likelihood function, for the support region Θ(c) and the profile support region Z(c) of the same level c,
Proof. Follows immediately from the definitions.
Lemma (1) makes precise the sense in which a value of z is in a profile support region if and only if it is in a support region for the full likelihood surface at the same level.
In the present case the profile likelihood does not have a unique maximum because it is constant across each intermarker interval. In fact:
Lemma 2. For the likelihood (8) with (x 1 , . . . , x z ) weakly isotonic and (x z , . . . , x n ) weakly antitonic, there will always be at least two adjacent intermarker intervals, say m i−1 < z < m i and m i < z < m i+1 , with equal and greatest profile likelihood L max (z).
Proof. If the isotonic sequence (x 1 , . . . , x i ) and antitonic sequence (x i+1 , . . . , x n ), with x i > x i+1 , maximize the likelihood then so do the isotonic sequence (x 1 , . . . , x i−1 ) and antitonic sequence (x i , . . . , x n ) (which has x i−1 < x i ), and vice versa.
Since I place much greater emphasis on obtaining a likelihood function than on obtaining a point estimate, I do not view the lack of a unique z as a serious problem. An ad hoc method of obtaining a point estimate from the profile likelihood function will be considered below.
A Computational Implementation
The profile likelihood only needs to be calculated once for each possible intermarker interval (m i < z < m i+1 ) in which the disease locus could lie, including the intervals outside the battery of markers (z < m 1 and m n < z). For each such z the pool adjacent violators algorithm (PAVA; Brunk 1955, Mukerjee and Wang 1993) is used twice, once on (x 1 , . . . , x z ) and once on (x z , . . . , x n ), to find the x that maximises max P L(z, x, P; D, C ). When calculating this for any given x, the term in (8) for the i-th locus may not be a unimodal function of the allele frequency parameters (whenever I ⊕ (D * ia i ) = 1 for more than one a i ; consider e.g. when These calculations are implemented (for biallelic markers) in a computer program poolmap, which can be distributed freely under the terms of the GNU general public licence (Free Software Foundation 1991). Source code and binaries for poolmap will be made available from the web site http://homepages.ed.ac.uk/tobyj/software/ .
Simulated Data and Performance Evaluation
Simulated Data
The parameter x of the model described above is related in a non-trivial way to the more ordinary parameters such as (i) the model for genealogy at the disease locus, (ii) the age, dominance and penetrance of the disease allele, and (iii) the map distances between the marker loci and the disease locus. Further, fixing these ordinary parameters specifies a probability distribution for x. I therefore chose to study simulated data generated using ordinarily parameterised models. The main test datasets were generated using the DMLE+ program of Reeve (2001, Reeve and Rannala 2002) by running it for 1000 updates while allowing proposals that altered the diseased haplotypes (the data) but not the parameters (i)-(iii) above. These simulations assumed the model described by Rannala and Reeve (2001) with a population growth rate of 10 −3 , a fraction 0.05 of all the diseased individuals present in the sample and a single rare recessive disease allele present in all chromosomes in the diseased sample. Non-ancestral blocks (including chromosomes in the control pool) were assumed to be in Hardy-Weinberg proportions and at linkage equilibrium. All marker loci were diallelic with allele frequencies drawn independently from a uniform distribution on [0.2, 0.8]. Taking z = 0 cM to denote the position of the lefthand marker, a battery of either n = 10, 28 or 82 markers were uniformly spaced over the interval Z m = [0 cM, 2 cM]. (It will be useful below to denote the inter-marker interval ∆z = 2cM/(n − 1) and the three marker-span interval Z 3m = [−2 cM, 4 cM]). The sample size was 50 diseased individuals and 100 control individuals (i.e. 100 and 200 haplotypes). For each simulation the location of the disease allele was drawn from a uniform distribution on the interval
, where m i is the map position of the i-th marker. I assumed a disease allele age of either 100 or 1500 generations, corresponding respectively to stronger and weaker LD between the disease locus and marker loci. A (co)dominant disease allele and/or the presence of phenocopy individuals will cause chromosomes not carrying the disease allele to be present in the diseased pool. These were modelled by replacing, with independent probability f p = 0.75 for each one, some chromosomes in the diseased pool with randomly generated control chromosomes. At least in continuous time models, the disease allele age and inter-marker interval ∆z are non-identifiable and the probability and likelihood functions depend only on their (identifiable) product. Therefore the simulation results described here for a disease allele age of 1500 generations and markers on a 2 cM interval should apply, at least as a good approximation, to the case of (say) an allele age of 150 generations and a 20 cM interval.
I also studied datasets simulated by generating a sample of 50 chromosomes from a large stationary Wright-Fisher population with mutation under the infinite sites model, For ESI preprint only.
and recombination (Hudson 1983 (Hudson , 2002 . One segregating site, with a derived allele at frequency > 0.2, was chosen at random to be the disease allele. All other segregating sites (on average there were 31) on an interval [−0.2, 0.4] (in units of 4N e r) were the markers. These simulations therefore violate at least three modelling assumptions made by the present method, those of a rare disease allele, of linkage equilibrium between markers on non-ancestral blocks of chromosome, and of no mutation in blocks of ancestral chromosome.
Testing
I have tested the method described here by exploring methods for generating confidence intervals. Because confidence intervals are endowed with a frequency property, they can be meaningfully tested by using simulations to examine the frequency of coverage of the true value of a parameter as a function of interval size. These tests serve two purposes. Firstly, if a method for calculating (approximate) confidence intervals can be found then they are a valuable supplement to the profile likelihood function. Secondly and more importantly, I argue that likelihood based inferences are only really meaningful if our experience with the nontrivial properties of likelihood functions translates across different classes of inference problem. The extent to which standard methods of generating confidence intervals work are an indication of how much the profile likelihood calculated by the present method behaves in a similar way to likelihood functions in inference problems with which we are more familiar. The quantity
i.e. twice the difference between the log-likelihood at MLE and at the true values of the parameters, is asymptotically pivotal in many classical likelihood based analyses. (Pivotal means that its sampling distribution does not depend on the true values (z * , x * , P * ).)
Confidence intervals that were regions of the high dimensional full parameter space and so would be difficult or impossible to represent, so I examined the distribution of the simpler quantity
across replicate simulations. If Λ z was [approximately] pivotal with (1 − α) quantile λ crit then Z(λ crit /2) would be an [approximate] (1 − α) confidence interval. If the profile likelihood was an ordinary likelihood, then we could adopt a Bayesian position, assuming (say) a uniform prior on Z 3m so that the posterior density for z was
Confidence intervals can be constructed from a posterior density; they are often called credibility intervals because they have additional properties desirable in likelihood based inference as well as the frequency property that defines a confidence interval (see e.g. Jaynes 1976 , Ghosh 1988 pp.170-174, Sprott 2000 . Therefore, the (1 − α) PseudoBayes Interval is the (1 − α) central probability interval of the density (14), i.e. the interval with equal probability mass in each excluded tail.
Measuring Information
Assessing the performance of a statistical method includes measuring how much information it extracts from the data. In statistical contexts definitions of information about a parameter z are almost ubiquitously based on the curvature of the log likelihood function, −d 2 ln L/dz 2 , evaluated at the MLE z = z. Such definitions cannot be applied meaningfully in the present case because the profile likelihood is piecewise constant and because there is no unique MLE. Further, such measurements are "local" because they describe only the behaviour of the likelihood function around the MLE and therefore may ignore important features of the likelihood function in cases where sample sizes are not very large. Therefore I use several more "global" ways of measuring information. The first way of measuring information that I consider is to use the lengths of the profile support regions (see equation (11)) at a range of critical values c. This has the disadvantage that it depends on an arbitrary choice of critical values c. For brevity I write |Z(c)| for the length of a profile support region and define it here as the minimum sum of lengths of a set of intervals that cover the entire region.
An analogue of using the |Z(c)| as a way of measuring information is to use the widths of (1 − α) PseudoBayes intervals (obtained from the density (14) above) for a range of values of α. Like the widths of support regions, this depends on arbitrary choices of α.
Let µ z and σ z be the mean and standard deviation of the density π(z). The standard deviation σ z is a useful summary of the width of the profile likelihood function because it is a scalar and is measured in the same units as z. (It may be interpeted in terms of the observed information after making a Gaussian approximation to the profile likelihood, where the approximation is made by finding the Gaussian density that has the same mean and variance as π(z).) The point estimate µ z can be interpreted as the MLE of the same Gaussian approximation. The sampling distribution of this point estimate can be studied using standard frequentist methods.
The final way of measuring information considered here is the information gain I G , defined as the decrease in entropy from (say) a uniform distribution on Z 3m to the distribution π(z). The advantage of I G over σ z is that it is expected to be more robust to the presence of small amounts of probability mass very far from the mean, which can cause large inflation of the variance. Its disadvantage is that it is not measured in such intuitively meaningful units. Readers unfamiliar with measure theory may wish to skip the rest of this paragraph, where the word 'measure' will be used in its technical sense. To define entropy for a continuous probability distribution a reference measure must be chosen, for which the natural choice here is u(·), the uniform distribution on Z 3m . Then the entropy of π(z) is
where (writing π(z) for density and π(Z) for measure, Z an arbitrary set)
is the Radon-Nikodym density of π(·) with respect to u(·), which in this case is the density π(z) renormalised to integrate to one with respect to the measure u(·). These definitions mean that the uniform density u(·) has entropy zero. The information gain is then defined in the usual way
and is nonnegative for all π(·) that are probability measures on Z 3m . Information defined in terms of entropy (17) has two appealing properties. Firstly, it is less arbitrary than σ z or other measurements based on moments or curvature. Indeed one could claim that entropy is the measure of information for discrete distributions. are equally informative, we should prefer measurements of information that reflect this. These ideas are in accord with the belief that inferences should be invariant under alternative parameterisations (Edwards 1992 pp.19-20, Sprott 2000 , although they can only be applied to measures and densities and not to point functions such as likelihoods.
To train our intuition about I G , note that when π(z) is the uniform distribution on some subinterval of Z 3m of width w (so σ z = w/(2 √ 3)) then I G = ln (|Z 3m |/w). Thus exp (−I G ) could be interpreted as the factor by which our estimate of z is made more precise, in this very specific sense.
Example Power Analysis: Comparison with Other Methods
It is possible to make a comparison between the amount of information available from analysis of DNA pool data and of fully resolved haplotypes by analysing simulated data sets using both poolmap, DMLE+, and an (essentially) single point method that I call the minimum p-value procedure.
Because of limits on computer time and difficulties with automating DMLE+, I have used it to analyse simulated data for only one particular combination of parameter values: 10 markers, an allele age of 100 generations, and no phenocopies. In analyses using DMLE+ the marker map positions, population growth rate, sample fraction, and disease allele dominance and penetrance were all assumed known, leaving the disease position, allele age and ancestral haplotype to be estimated. To speed up convergence the chains were restricted to the interval [(m 1 + m 2 )/2, (m n−1 + m n )/2] where m i is the map position of the i-th marker. Nine chains were run in parallel and convergence was diagnosed using the estimated potential scale reduction statistic R , which is based on the variation in state between chains relative to that within chains over time (for details see Gelman 1996) . If the multiple chains are initially overdispersed over the parameter space, R declining towards 1 indicates convergence. Ideally, output would be collected from a pre-determined number of samples after R had fallen below some specified value, but unfortunately DMLE+ does not have this facility. Therefore, the nine chains were run for a total of 10 6 iterations each, and only the (1000-fold thinned) samples generated after R had fallen below the value 1.1 were used. In some cases no such samples were generated in the 10 6 iterations.
I compared the amount of information available in multilocus allele frequency data to the information in fully resolved haplotypes by using the measures of information described above to compare the density π(z) (corresponding to the profile likelihood from poolmap; equation (14)) to a posterior density estimated using DMLE+. Comparing (proxies for) the widths of region estimates generated by two methods is meaningful only if both methods produce correct posterior densities. I show below that it is approximately true for poolmap, and assume that it is so for DMLE+ because the same model is used for simulation and reanalysis.
Moment based summaries and sizes of confidence intervals can be calculated directly from the samples output by DMLE+. The information gain I G for the DMLE+ posterior is only defined for a function that is strictly continuous with respect to the reference measure. I obtained such a function by first estimating the density at 512 points (uniformly spaced over the range of the samples ±3 bandwidths) using a Gaussian kernel with the bandwith given by equation (3.31) of Silverman (1986 p.48) , and then interpolating linearly between those points plus two extra points (−2cM, 0) and (4cM, 0). (This procedure gives underestimates of up to 8% for 10 4 samples simulated from uniform distributions.) Although DMLE+ can generate histogram summaries based on unthinned samples, this feature could not be used because the subset of samples used cannot be made to depend on R , only on a pre-determined burn-in time.
I also compared the point estimate µ z obtained by poolmap against the simple point estimator that is the map location of the marker locus that has the smallest p-value in a χ 2 test on the 2 × 2 contingency table of allele counts. I call this point estimator z min p . (Ties were broken by taking the mean map location of the tieing markers.) This is essentially (but not technically) a single point method, since each p-value depends only on the data for one marker locus, but z min p depends on all the data.
Results
The main result is that I have written down a method for calculating a profile likelihood function for the position of a disease locus, which is (i) based on a relatively robust and assumption free model, and (ii) can be calculated from the allele frequencies (only) in samples of unrelated diseased and control individuals. I have proved two rather minor but general results that show (lemma 1) a way in which the profile likelihood is can be interpreted as if it was an ordinary likelihood and (lemma 2) set an absolute maximum on the precision of estimates that can be obtained by this method, which is two intermarker intervals.
The remaining results concern the performance of this and other methods on simulated data sets. The main body of simulations consider three marker densities, 10, 28 or 82 markers uniformly spaced over a 2cM region. The three combinations of parameter values used for the simulations are expected to cover a range of likely situations. An allele age of 100 generations (and no phenocopies) causes strong association between marker allele and disease status, with disease alleles embedded in blocks of ancestral chromosome extending on the order of 1cM either side of it, so that junctions between ancestral and non-ancestral blocks are scattered over the region spanned by the markers. An allele age of 1500 (and no phenocopies) generates weaker association, with junctions on the order of 0.07cM either side of the disease locus, which is (for 10, 28 or 82 markers) roughly one third, one or three inter-marker intervals (respectively). An allele age of 100 generations but with phenocopies where on average 75% of chromosomes in the disease pool are phenocopy chromosomes corresponds (for example) to the situation where there is a dominant fully penetrant disease allele at a frequency of 0.005, Hardy-Weinberg proportions at the disease locus, and a phenocopy rate of 0.01 in the population (and hence a risk ratio of ∼ 100). This is a high fraction of phenocopies, and makes the association between marker allele and disease status much weaker; these will be challenging data sets to extract information from. A smaller set of simulations violate at least three modelling assumptions made by For ESI preprint only.
the present method, those of a rare disease allele, of linkage equilibrium between markers on non-ancestral blocks of chromosome, and of no mutation in blocks of ancestral chromosome.
Testing the Method
In the simulations described here the distribution of the quantity Λ z (as defined in equation (13)) over any of the sample spaces examined was not at all like a χ 2 distribution, being much longer tailed with a variance much greater than its mean squared (table 1) . Further, this sampling distribution obviously varies with the parameters, even for fixed n (table 1) , and so could not be said to be even approximately pivotal. Therefore, attempting to construct confidence intervals using a sampling distribution for Λ z seems futile, even if that sampling distribution was to be estimated by simulation. This result is hardly surprising, because the theory that quantities analogous to Λ z should be χ 2 distributed (see e.g. Kendall and Stuart 1967 pp.224-231) requires (i) the likelihood function be continuous in all the parameters, which it is not here, (ii) is only asymptotically correct for large samples of i.i.d. observations, (iii) applies only to ordinary likelihoods and not to profile likelihoods, and (iv) applies for the sampling distribution of the likelihood function with parameters held fixed, whereas here the parameter x itself has a distribution indexed by the "ordinary" model parameters.
Although conservative critical values for Λ z could be estimated from table 1, they would only apply for the combinations of parameters simulated and one should be sceptical about extrapolating them to a broader range of parameter values. It is just about worthwhile reasonable to speculate that when there are no phenocopies a critical Λ z of 4, corresponding to the sometimes used rule of thumb of 2 support units (e.g. Edwards 1992 p.76), would generate better than 90% confidence intervals. Further exploration of this avenue does not seem not very worthwhile since I will now demonstrate a better method for constructing confidence intervals. Figure 2 shows frequency of covering the true disease allele position z * as a function of interval size, for PseudoBayes intervals as described in section 2.4.2. (This figure is like a "qq plot" but measures cumulative probabilities working out from the center of the distribution rather than in from one end.) Figure 2 shows that when the allele age is 100 generations, either without (f p = 0) or with (f p = 0.75) phenocopies, the (1 − α) sized interval has greater than (1 − α) coverage frequency and therefore could be treated as a conservative 100(1 − α)% confidence interval. For allele age 1500 generations this is true when (1 − α) ≤ 0.9, which is a useful range of sizes of confidence intervals to be able to construct. To guide the interpretation of figure 2, consider a more familiar model where information about the disease allele position comes from N independent observations Z = (Z 1 , . . . , Z N ), each drawn from a Gaussian distribution with known variance, N(z * , σ 2 ). The likelihood function would then be proportional to a Gaussian density
Now suppose that the same interval construction procedure was used, but calculated using either a correct or an incorrect value of N . The interval could for example be twice the correct width (N one quarter of the true value; upper dotted line), the correct width (1:1 dotted line) or half the correct width (N four times the true value; lower dotted line). Based on inspection of figure 2, it seems reasonable to conclude that the net effect of the non-parametric model and the conservative elimination of nuisance Allele age was 1500 generations (red) or 100 generations (black for no phenocopies and blue for 0.75 phenocopies). Number of markers was 10 (dashed), 28 (dot-dashed) or 82 (solid). Coverage frequency estimated by 1000 simulations. Dotted "guide"-lines show equivalent results for a simple Gaussian location model when the scale is known correctly (diagonal 1:1 line) or when it is known in error by a factor of two. Thus the top faint line corresponds to "confidence intervals" that are (in a particular sense) too large by a factor of two.
parameters means that the profile likelihood is up to twice as wide as some more ideal analysis of the same data, and is in a particular sense equivalent to throwing away up to 75% of the information (measured in units of i.i.d. observations). Tables 2 and 3 and figure 3 show how the performance of the method described here improves with increasing marker density, for different strengths and patterns of association between the markers and disease status. All meaures of information considered confirm the expected result that the profile likelihood function becomes narrower (when measured in cM) and more informative as the marker density increases. All the measures are correlated, e.g. the correlation between (2 √ 3)σ z and (|Z 3m | exp (−I G )) ranges between 0.88 and 0.97 (these measures would be equal if all π(z) were uniform densities on some subinterval). The imperfect correlation means that it will not always be adequate to use a single measure.
Performance
For the simulations with no phenocopies there are relatively rare cases of a small information gain, I G 1 (these appear as small bumps in the densities shown in figure 3 ). These occur when the disease locus is near one extreme of the marker battery; in some such cases the profile likelihood is (near to) maximum for z < 0cM or z > 2cM. When only the subset of simulations where z * ∈ [0.5cM, 1.5cM] is considered, the frequency of these essentially uninformative cases vanishes. It appears from table 2 and figure 7 that in many cases performance scales less than linearly with marker density, i.e. where the information can be measured in units of ∆z it is mostly an increasing function of the number of markers. Thus e.g. a three-fold increase in marker density will yield a less-than-three-fold decrease in the size of a region estimate.
Lemma 2 means that the minimum width σ z that can be achieved by poolmap is ∆z/ √ 3, and the maximum information gain is ln (|Z 3m |/(2∆z)) where ∆z is the shortest total length of any two adjacent intermarker intervals.
The mean run times shown in figure 4 are approximate, but appear to be roughly exponential in the number of markers. Extrapolating using a simple least squares regression of log (run time) onto marker number does not give rise to much optimism about analysing large (> 150 marker) data sets using the present implementation of the method. Table 3 : Performance of the poolmap method measured by the width σ z and information gain I G of the density π(z). Quantiles reported are the observed quantiles of 1000 replicate simulation results. 
Comparison with Other Methods
It is of some interest to determine the amount of information that can be obtained using (say) the poolmap algorithm relative to the amount of information that could be obtained if fully resolved haplotypes were available and were analysed. Put differently, how much information is lost by discarding phase information by using DNA pools. It is also interesting to compare poolmap against the simple procedure of picking the map position of the marker with the smallest p-value as a point estimate for the position of the disease locus position. Figure 5 shows an example simulated data set analysed using these three methods. Both in the example in figure 5 and in general (figure 6) it is clear that the poolmap algorithm is able to extract less information from allele frequency data than the Bayesian method DMLE+ is able to extract from fully resolved haplotypes. It is not really clear how to estimate the relative contributions to this difference from the conservative methodology of poolmap and the intrinsically less informative data that it takes as input. Figure 6 shows that, when information is measured using the information gain I G , it looks as though the Bayesian analysis of haplotypes with 10 markers is roughly equivalent to using poolmap to analyse allele frequency data with 28 markers, i.e. 27/9 = 3 times greater marker density. A slightly different conclusion is reached by considering σ z as a measure of information. A plot in the style of figure 6 shows only the the distribution of σ z for DMLE+ analysis with n = 10 lies somewhere between those for poolmap analysis with n = 28 and n = 82. By "matching quantiles" of the distributions, as shown in figure 7 , it can be estimated that Bayesian analysis of haplotypes with 10 markers is roughly equivalent to using poolmap to analyse allele frequency data with a 42/9 4.7 times greater marker density. These results should be treated as being totally contingent on the one set of parameter values used for these simulations.
Surprisingly, at first inspection there was no clear difference between the performance of the point estimator µ z derived from poolmap and the minimum p-value procedure. A technical point is that we're considering the error distribution averaged over the uniform distribution of z * , or the error distribution for fixed z * and position of the battery of markers an (ancilliary) random variable. This imposes a symmetry that makes both estimators unbiased. Table 4 shows that often z min p was more efficient, meaning that its error distribution has a smaller variance. However, when the error distributions are not Gaussian it is not sufficient to simply compare the efficiencies. As an illustrative example, figure 8 shows the error distributions for n = 28 markers, allele age 1500 generations and no phenocopies. Even though it has greater variance, the distribution (17)) of the estimated posterior density and the normalised profile likelihood respectively. Coloured lines show the distributions for 50 simulations where both DMLE+ and poolmap were used to analyse the same data. Black lines show results for poolmap from 1000 replicates per value of n. To a fair approximation, the distribution of I G for DMLE+ with n = 10 matches the distribution of I G for poolmap with n = 28. Figure 7 : Red lines show a set of (.1, .3, .5, .7, .9) quantiles plotted as (dot, dot-dash, dash, dot-dash, dot) for the distribution of the width σ z of the profile likelihood, obtained by the method described here. Data are for allele age 100 generations, no phenocopies, 0.5cM ≤ z * ≤ 1.5cM and n = 82, 28 and 10 markers going left to right. The quantiles are plotted as a function of the minimum possible value of σ z (by lemma 2). The same set of quantiles of the distribution of σ z obtained using DMLE+ to analyse datasets with n = 10 markers are shown as horizontal green lines. (Note that these are poorly estimated since only 50 simulations were used.) All DMLE+ lines intercept the respective poolmap lines at 43 or fewer markers. Table 4 : Comparison of point estimates obtained by the poolmap method and the minimum p-value method. In both cases the estimates are unbiased. The sampling distribution of the error, for 1000 replicate similations in each case, is summarised by its standard deviation, and the 0.5 and 0.9 quantiles of its absolute values. The significance of the difference for each summary is indicated by superscripted + or − for p ≤ 0.01 and (+) or (−) for 0.01 < p ≤ 0.05, estimated from 1000 bootstrap resamplings. Lines show estimated densities of µ z − z * (poolmap; red) and z min p − z * (minimum p-value; blue). Points show µ z − z * against σ z . One point at µ z − z * −1.6cM is not shown. Parameters were 28 markers on the 2cM interval, allele age 1500 generations and no phenocopies. of µ z is more concentrated on the true value, but with more outliers. This is reflected in the quantiles of the distribution of absolute error (table 4) and in its greater kurtosis (not shown). The important feature of using poolmap to obtain a point estimator such as µ z is that, in most cases, it gives a warning that the estimator is unlikely to be close to the true value by returning a relatively flat likelihood function. This is shown by the association between large error and large associated values of σ z , shown as points in figure 8 . This behaviour is found for almost all combinations of parameter values and marker densities. Thus, one may reasonably prefer the µ z point estimator over the the z min p point estimator.
Restricting the analysis to only the simulations where the disease locus position is in the central part of the marker range, z * ∈ [0.5cM, 1.5cM], gives results where µ z is generally more efficient than z min p , as shown in table 5. This highlights a fundamental problem with assessing estimators by their efficiency, that the results depend on the choice of sample space which is to a high degree arbitrary. (Conditioning on z ∈ [0.5cM, 1.5cM] hardly changes the appearance of e.g. figure 8 , only removing the extreme errors from the poolmap distribution and making its density a little higher at the origin.) In the data for allele age 1500 generations and allele age 100 generations with 75% phenocopy chromosomes we see that the poolmap point estimates becore more efficient that z min p as n increases, which is a little like the often observed result that likelihood based point estimates are asymptotically more efficient (although usually in the limit of the number of i.i.d. observations). Figure 9 shows the error distribution for point estimates obtained by poolmap and For ESI preprint only.
by the composite likelihood method of Hudson (described at the ESI meeting in December 2003; reference a preprint in this series?). It can be seen that although Hudson's composite likelihood method produces superior point estimates, poolmap produces reasonable point estimates and seems robust to violations of its modelling assumptions.
(For a more direct comparison between the methods, the point estimate from poolmap was taken as the midpoint of the region where the ln profile likelihood was 0.01 units below its maximum, and both point estimates were restricted to the [−0.2, 0.8] interval (in units of 4N e r).) 
Discussion
In this paper I have described a multipoint method for disease gene mapping in a case and control design study that takes a very different approach to those described previously (see references in section 1). From a practical perspective, the two most important differences are that (i) the present approach uses only allele frequency data at marker loci and not haplotype information. It can therefore be used on data collected using DNA pools, and (ii) it is robust to (unrelated) phenocopy individuals or chromosomes occuring in the diseased sample at an arbitrary rate. At the time of writing it is unique among multipoint methods in both these respects. Here, multipoint means that the method uses data from all markers simultaneously to weigh the evidence for the disease locus being at a particular point or in a particular region. Here, multipoint means that the method uses data from all markers simultaneously to weigh the evidence for the disease locus being at a particular point or in a particular region. Dick Hudson pointed out to me at the ESI meeting that the composite likelihood For ESI preprint only.
(the product of all pairwise likelihoods) does not use phase information, and so could be applied to data from DNA pools. From a more theoretical perspective the present method uses a nonparametric model for the genealogy at the disease locus, whereas all previous multipoint methods (see references in section 1) have used parametric models. Here, nonparametric means that the dimensionality of the parameter x used here is equal to the number of marker loci n, whereas parametric approaches employ a parameter with fixed dimensionality regardless of n. (Note that all pure likelihood approaches use a nonparametric model for allele frequencies in non-ancestral blocks of chromosome, and that the parametric/nonparametric distinction does not exist in the Bayesian context because any "nonparametric" vector parameter has a prior of fixed dimension.) The practical implication of this difference is that the present method is expected to be more robust, because less assumptions are made, but also less powerful. Investigators should be interested in trading power for robustness when there is (or at least should be) model uncertainty. That is, they should prefer to make a noninference than a misinference. The other model assumptions made here are very similar to those made by most previously described case and control multipoint mapping methods. The assumption made here, of linkage equilibrium in nonancestral blocks of chromosome, was addressed by Liu et al. (2001) and by Morris et al. (2002) , who modelled allelic state as a first order Markov process along the chromosome. The present method could in principle be modified in the same way, although (at least when all controls and all diseases are in single pools) it is not clear whether there is any information in the data about the pairwise linkage disequilibria and so whether the profile likelihood approach would work.
On the subject of nonparametric models Fisher (1971 p.49) cautioned "In inductive logic, however, an erroneous assumption of ignorance is not innocuous; it often leads to manifest absurdities". Fortunately, in this case it doesn't. Pretending to be ignorant about the depth and shape of the genealogy of the disease locus (that is, considering all x with monotonicity patterns consistent with a given z to be equally plausible a priori ) does not seem to lead to misinferences. One cannot say for sure that the rare cases indicated by table 1 where Λ z is large, i.e. where the profile likelihood is much higher at some point away from the true position of the disease locus than at it, are misinferences. This is because it may well be that in those cases the true likelihood function is also strongly peaked away from the true position.
In likelihood based inference, if there is agreement about the model then there is no need to evaluate the "statistical performance" of the likelihood function. However, the method used here may be contraversial because it uses a nonparametric model and eliminates nuisance parameters by calculating a profile likelihood. Heeding the cautions of Fisher (1971 p.49, quoted above) and of Basu (Ghosh 1988 pp.57-59), careful examination of the performance of the method was warranted. To do this it was neccessary to move outside the domain of validity of the likelihood principle and use more ad hoc and neccesarily frequentist methods. These involved estimating the probability with which various intervals constructed from the profile likelihood contain the true value of the disease allele position, where probability is understood to be the long run frequency in independent simulations. The approximately correct behaviour of confidence intervals constructed by the PseudoBayes procedure lends support to my claim that the profile likelihood from this nonparametric model can be interpreted in approximately the same way as the ordinary likelihood from a parametric model.
There is no definitive way to make a comparison between the estimated marginal posterior density produced by DMLE+ with the profile likelihood produced by poolmap. (Indeed there is no definitive way to compare two posterior densities unless a utility function can be agreed (see e.g. Lindley 2000).) I chose to turn the likelihood function into a density rather than try to interpret the posterior density as a likelihood function. My main reason for this choice is that scalar summaries of the informativeness of a density could be chosen less arbitrarily, whereas the only summaries of a likelihood are the widths of level c support intervals which require arbitrary choice of c.
I should stress that I am not advocating using the density π(z) instead of the likelihood function L max (z; D, C ) to make inferences in any real inference situation. I advocate using the density π(z) only for testing and comparative study of the method, in the absence of any obvious better procedure.
Applying the method described here on simulated data showed that the method works, in the sense that in every case some information about the position of the disease locus was extracted from the multilocus allele frequency data; i.e. the profile likelihood was not constant for all z. This result was not a priori obvious because it was not clear how much information is present in the allele frequency data alone, whether a nonparametric model would extract any of that information, and whether any extracted information would survive the conservative transformation to a profile likelihood. (Although Table 2 shows that in some of the simulations the length of the 2-unit profile support region Z(2) was infinite, in all cases this interval extended beyond either one end of the battery of markers or the other and not both.)
I have performed only a single example power analysis, comparing the amount of information present in fully resolved haplotypes against that in allele frequency data only. More power analyses are not presented because (i) the parameter space is too vast to hope to make any general statement, and (ii) I was unable to devise a general way (other than human intervention on a case by case basis) to obtain satisfactory mixing of the Markov Chain Monte Carlo method used by DMLE+ on simulated data sets. The methods illustrated here for presenting the result of a power analysis (figures 6 and 7) show that a reasonably meaningful power analysis can be performed to compare possible gene mapping strategies that vary how many markers are typed and whether phase information is acquired.
In the power analysis presented here, I have shown the DMLE+ program in its best light. I used it only on data simulated under exactly the same model used in the reanalysis, and only used output where multiple chains had converged according to a stringent criterion. Further, the PseudoBayes procedure for obtaining a density π(z) from the poolmap output assumes a uniform prior on a ∼ 3× longer interval Z 3m than the prior assumed by DMLE+. Although this may have lead to an inflated estimate of the difference in performance between DMLE+ and poolmap, the way I did things reflects my assumption that in an analysis of real data, some human intervention would always ensure adequate convergence of a DMLE+ analysis, even if a prior was used that extended outside the region spanned by the marker battery.
Other recent papers on the subject of testing the significance of association between phenotype or disease status and allele frequency at a single locus in the context of DNA pools (Risch and Teng 1998 , Bader et al. 2001 , Jawaid et al. 2002 have focussed on significance testing and did not directly address the problem of estimating the position of the disease gene. If only a single typed locus is considered at a time, then it is possible to test for association by calculating a χ 2 , Z max or other test statistic and determine a p-value under the null hypothesis that the affecteds and controls are sampled from the same distribution (see e.g. Lange 1997 pp. 52-62) . This null hypothesis is correct if there is no linkage disequilibrium between the typed locus and the disease locus (and also no other association between the typed locus and disease phenotype), which is roughly what is expected if none of the disease loci are closely linked to the typed locus. However, to map a disease locus it is not sufficient to simply test for significance. A region estimate for the position of the disease locus is required. This is because at the end of a fine scale mapping effort an important question an investigator should ask is "Should I type more markers and improve the resolution of mapping, or should I attempt positional cloning on the basis of my current position estimate?". Obviously this question cannot be answered by a point estimate, only by a region estimate. If many loci have been typed (e.g. in a genome-wide scan), it is possible to make a region estimate by calculating p-values for each typed locus in turn, and then saying that it is most plausible that the disease locus lies in some interval where low p-values are concentrated. Even if a correction is made for multiple comparisons, this approach is not a good one because at the present time only ad hoc and probably post hoc methods are available to make such a region estimate (i.e. there is no known way to calculate a confidence interval), and it may lead to inefficiently large region estimates because highly significant p-values may occur over a large region (see e.g. figure 5 , or figure 2 of Martin et al. 2000) . Such approaches will always be dogged by the problem that p-values confound effect size (amount of LD) and power (e.g. heterozygosity of marker), both of which typically vary across markers. Frequentist single point methods will tend to lead to inferences that are incoherent (in its nontechnical sense). In contrast, we can use likelihood based multipoint methods to make inferences that are more coherent, or Bayesian methods to make inferences that are coherent in both the colloquial and technical senses. Despite these theoretical criticisms, in practice the minimum p-value method (which Kaplan and Morris (2001a,b) claim is a "good" estimator) seems to perform remarkably well against my likelihood based method. Unfortunately for the minimum p-value method, efficiency of point estimation should not be the criterion by which mapping analyses are judged. The appropriate criterion is the ability to produce a nested set of region estimates with some quantitative measure of the support or confidence for each one. By this criterion methods that produce a likelihood or posterior density that is a function of map or physical position succeed and can be compared against each other, and the minimum p-value method fails because it does not produce any region estimate at all.
